LDL Cholesterol: New Research & How It Impacts Health
- Scientists at the National Institutes of Health (NIH) have made a significant stride in understanding how low-density lipoprotein cholesterol, or LDL-C, accumulates in the body.
- the study, published in Nature, sheds light on the mechanisms by which LDL-C contributes to cardiovascular disease, the world's leading cause of death. The findings could pave the...
- Alan Remaley, who heads the Lipoprotein Metabolism Laboratory at the NIH's National heart, Lung, and Blood Institute and co-senior author of the study, emphasized the importance of understanding...
New NIH research deciphers how “bad” cholesterol (primary_keyword)—LDL-C—binds to its receptor, offering a breakthrough in cardiovascular disease understanding. This critical study details the accumulation process of LDL-C, a major contributor to heart disease, perhaps paving the way for personalized treatments. Scientists utilized advanced imaging technology to visualize LDL structure and pinpoint genetic mutations tied to elevated LDL-C levels (secondary_keyword). The study’s insights could refine treatments, like statins, enhancing effectiveness. News Directory 3 reports that the research team is now focused on developing targeted therapies to correct dysfunctional interactions. these therapies promise to make a meaningful impact in lowering LDL-C and preventing heart disease.Discover what’s next in the treatment of high cholesterol.
NIH Study Reveals How Bad Cholesterol (LDL-C) Builds Up
Updated June 08, 2025
Scientists at the National Institutes of Health (NIH) have made a significant stride in understanding how low-density lipoprotein cholesterol, or LDL-C, accumulates in the body. This “bad” cholesterol is a primary driver of heart disease, and the new research clarifies how LDL-C’s main structural protein binds to its receptor, initiating the process of clearing LDL-C from the bloodstream.
the study, published in Nature, sheds light on the mechanisms by which LDL-C contributes to cardiovascular disease, the world’s leading cause of death. The findings could pave the way for tailoring LDL-C-lowering treatments, such as statins, to enhance their effectiveness.
Dr. Alan Remaley, who heads the Lipoprotein Metabolism Laboratory at the NIH’s National heart, Lung, and Blood Institute and co-senior author of the study, emphasized the importance of understanding LDL-C’s structure to combat cardiovascular disease.
Previously, visualizing the structure of LDL-C, especially its interaction with its receptor (LDLR), had eluded scientists. Normally, LDL-C binds to LDLR, triggering its removal from the blood. Tho, genetic mutations can disrupt this process, leading to LDL-C buildup and plaque formation in arteries, a precursor to atherosclerosis and heart disease.
The new research employed advanced technology to visualize this critical stage,offering unprecedented insight into LDL-C’s structure.
Dr. Joseph Marcotrigiano, chief of the Structural Virology Section at NIH’s National Institute of Allergy and Infectious Diseases and co-senior author, noted the complexity of LDL-C due to its size and variability. He added that the high-resolution imaging allowed them to dissect how it functions in the body.
Using cryo-electron microscopy, the researchers visualized the entire structural protein of LDL-C bound to LDLR. They then used artificial intelligence to model the structure and pinpoint genetic mutations associated with elevated LDL-C. The AI software developers recently received the Nobel Prize in Chemistry.
The study revealed that many mutations mapped to the LDL-C and LDLR connection site were linked to familial hypercholesterolemia (FH), an inherited condition characterized by impaired LDL-C uptake and very high LDL-C levels, leading to early heart attacks. These FH-associated variants tended to cluster in specific regions on LDL-C.
These findings may lead to targeted therapies to correct dysfunctional interactions caused by mutations. The researchers suggest that understanding precisely how LDLR binds to LDL-C could also aid in designing new drugs to lower LDL-C in individuals without genetic mutations but who have high cholesterol and are taking statins.
What’s next
Future research will focus on developing targeted therapies to correct dysfunctional interactions between LDL-C and its receptor, potentially leading to more effective treatments for high cholesterol and heart disease prevention.